¿Qué se puede hacer al respecto? | 08 FEB 16

¿Por qué nunca se ha demostrado que el cribado del cáncer salve vidas?

"Los daños del cribado son ciertos, pero los beneficios en la mortalidad general no lo son”
INDICE:  1. Página 1 | 2. Referencias

1 Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol2005;23:293-300.
2 Zahl PH, Jørgensen KJ, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013;109:2014-9.
3 Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
4 Kopans DB. Mammograms save lives. Wall Street Journal 2014 May 22. www.wsj.com/articles/SB10001424052702304547704579564440536353948.
5 Prasad V. Powering cancer screening for overall mortality. Ecancermedicalscience 2013;7:ed27.
6 Newman DH. Screening for breast and prostate cancers: moving toward transparency. J Natl Cancer Inst 2010;102:1008-11.
7 Prasad V. But how many people died? Health outcomes in perspective. Cleve Clin J Med 2015;82:146-50.
8 Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-73.
9 Saquib N, Saquib J, Ioannidis JP. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. Int J Epidemiol 2015;44:264-77.
10 Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
11 Moayyedi P, Achkar E. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. Am J Gastroenterol 2006;101:380-4.
12 Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4.
13 Gallina A, Suardi N, Montorsi F, et al. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008;123:647-52.
14 Fang F, Keating NL, Mucci LA, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 2010;102:307-14.
15 Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013;88:790-8.
16 Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med 2004;350:2010-1.
17 Fall K, Fang F, Mucci LA, et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med 2009;6:e1000197.
18 Haines IE, Gabor Miklos GL. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. J Natl Cancer Inst 2013;105:1534-9.
19 National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
20 Hunt I, Siva M, Southon R, Treasure T. Does lung cancer screening with chest X-ray improve disease-free survival? Interact Cardiovasc Thorac Surg 2006;5:483-7.
21 Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax 2003;58:784-9.
22 Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo lung project: impact of extended follow-up. J Natl Cancer Inst 2000;92:1308-16.
23 Juffs HG, Tannock IF. Screening trials are even more difficult than we thought they were. J Natl Cancer Inst 2002;94:156-7.
24 Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five  nnual screening rounds with low-dose CT. Thorax 2012;67:296-301.
25 Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 2013;119:1381-5.
26 Humphrey L, Deffeback M, Pappas M, et al. Screening for lung cancer: systematic review to update the US Preventive Services Task Force recommendation. Agency for Healthcare Research and Quality, 2013.
27 Hoffmann TC, Del Mar C. Patients’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2015;175:274-86.
28 Domenighetti G, D’Avanzo B, Egger M, et al. Women’s perception of the benefits of mammography screening: population-based survey in four countries. Int J Epidemiol2003;32:816-21.
29 Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011;107:882-91.
30 Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013;6:CD001877.
31 Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns—getting past uninformative persuasion. N Engl J Med 2012;367:1677-9.
32 Hersch J, Barratt A, Jansen J, et al. The effect of information about overdetection of breast cancer on women’s decision-making about mammography screening: study protocol for a randomised controlled trial. BMJ Open 2014;4:e004990.
33 Johansson M, Brodersen J. Info
34 Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 2014;370:1965-7.
35 Heleno B, Thomsen MF, Rodrigues DS, Jørgensen KJ, Brodersen J. Quantification of harms in cancer screening trials: literature review. BMJ 2013;347:f5334.
36 Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013;11:106-15.
37 Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014;311:1327-35.
38 Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
39 Patz EF Jr, Pinsky P, Gatsonics C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-74.
40 Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587.
41 Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013;310:797-8.
42 Baker SG, Kramer BS, Prorok PC. Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol 2002;2:11.
43 Lauer MS, D’Agostino RB Sr. The randomized registry trial—the next disruptive technology in clinical research? N Engl J Med 2013;369:1579-81.
44 Zhu CS, Pinsky PF, Kramer BS, et al. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst 2013;105:1684-93.
45 Bell KJ, Bossuyt P, Glasziou P, Irwig L. Assessment of changes to screening programmes: why randomisation is important. BMJ 2015;350:h1566.
46 Roth JA, Sullivan SD, Goulart BH, Ravelo A, Sanderson JC, Ramsey SD. Projected clinical, resource use, and fiscal impacts of implementing low-dose computed tomography lung cancer screening in Medicare. J Oncol Pract 2015;11:267-72.
47 Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012;157:571-3.
48 Doshi P. From promises to policies: is big pharma delivering on transparency? BMJ 2014;348:g1615.
49 Doshi P, Goodman SN, Ioannidis JP. Raw data from clinical trials: within reach? Trends Pharmacol Sci 2013;34:645-7.
50 Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:f2865.
51 Benard VB, Thomas CC, King J, et al. Vital signs: cervical cancer incidence, mortality, and screening—United States, 2007-2012. MMWR Morb Mortal Wkly Rep 2014;63:1004-9.
52 Neugut AI, Lebwohl B. Colonoscopy vs sigmoidoscopy screening: getting it right. JAMA 2010;304:461-2.
53 Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
54 Birnbaum JK, Feng Z, Gulati R, et al. Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2015;24:677-82.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024